Maruho
As of the edition of 20 October 2026, Maruho runs 15 drugs, 9 of them marketed; it is on route A at 2 targets and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 9 |
| Went quiet | 4 |
| Stopped | 2 |
| Total | 15 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Acetylcysteine | none listed | 0 |
| Metronidazole | none listed | 0 |
| Propranolol | none listed | 4 |
| Glycopyrronium | none listed | 10 |
| Benzoyl peroxide | none listed | 0 |
| Clobetasol propionate | none listed | 2 |
| Nemolizumab | Ends 2036 (computed from the first US licence) | 2 |
| Amenamevir | none listed | 0 |
| Ozenoxacin | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 2 targets, route B at 2 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Maruho needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Skin and connective tissue: 24 trials led
- Infections: 9 trials led
- Immune system: 3 trials led